LAUSR

Coagulation Antiplatelet drugs are commonly used to prevent stroke in high-risk patients. Unfortunately, a frequent side effect of these drugs is excessive bleeding. To improve the safety margin of antiplatelet agents, Wong et al. identified a new target for treatment, a platelet receptor called PAR4. They developed a small-molecule drug and evaluated its efficacy and safety in animal models. The new drug was no less effective and had a much larger therapeutic window than the widely used antiplatelet agent clopidogrel. Sci. Transl. Med. 9 , eaaf5294 (2017).